Transplant Co-Morbidity
Gene: DPYD
Monoallelic loss of function variants in this gene are associated with an increased risk of toxicity in cancer patients receiving fluoropyrimidine chemotherapy. Biallelic variants result in dihydropyrimidine dehydrogenase deficiency, an error in pyrimidine metabolism associated with thymine-uraciluria.
https://www.pharmgkb.org/gene/PA145/overview
Sources: Expert listCreated: 24 Aug 2023, 1:53 p.m. | Last Modified: 24 Aug 2023, 1:56 p.m.
Panel Version: 0.4
      Mode of inheritance
      BOTH monoallelic and biallelic, autosomal or pseudoautosomal
    
      Phenotypes
      Dihydropyrimidine dehydrogenase deficiency MIM#274270; 5-fluorouracil toxicity MIM#274270; Disorders of pyrimidine metabolism
    
Gene: dpyd has been classified as Green List (High Evidence).
Gene: dpyd has been classified as Green List (High Evidence).
gene: DPYD was added gene: DPYD was added to Transplant Co-Morbidity Superpanel. Sources: Expert list Mode of inheritance for gene: DPYD was set to BOTH monoallelic and biallelic, autosomal or pseudoautosomal Phenotypes for gene: DPYD were set to Dihydropyrimidine dehydrogenase deficiency MIM#274270; 5-fluorouracil toxicity MIM#274270; Disorders of pyrimidine metabolism Review for gene: DPYD was set to GREEN